PENGARUH PENGGUNAAN OBAT GOLONGAN CALSIUM CHANNEL BLOCKERS (CCB) DIBANDINGKAN ANGIOTENSIN RECEPTOR BLOCKERS (ARB) TERHADAP LUARAN KLINIS PASIEN HIPERTENSI DENGAN GANGGUAN GINJAL DI RSI IBNU SINA BUKITTINGGI

Annisa Rahim; Tika Afriani; Ariesta Kirana Efmisa

doi:10.1144/jscpr.v2i1.401

Authors

Annisa Rahim Universitas Mohammad Natsir Bukittinggi, Indonesia
Tika Afriani Universitas Mohammad Natsir Bukittinggi, Indonesia
Ariesta Kirana Efmisa Universitas Mohammad Natsir Bukittinggi, Indonesia

DOI:

https://doi.org/10.1144/jscpr.v2i1.401

Keywords:

Hypertension, Chronic Kidney Disease, Calcium Channel Blockers, Angiotensin Receptor Blockers

Abstract

Hypertension is a major risk factor for chronic kidney disease (CKD) with a complex bidirectional relationship. Appropriate selection of antihypertensive drugs in patients with hypertension and end-stage CKD is crucial to prevent disease progression and improve clinical outcomes. This study aimed to compare the effectiveness of Calcium Channel Blockers (CCB) and Angiotensin Receptor Blockers (ARB) on changes in blood pressure and kidney function in patients with hypertension and stage 5 CKD at RSI Ibnu Sina Bukittinggi. A descriptive-analytic design with a retrospective approach was employed, involving 30 patients who met the inclusion criteria from a total of 78 patients during the period February 2023–December 2024. Parameters observed included systolic/diastolic blood pressure, serum creatinine, glomerular filtration rate (GFR), and urea levels before and after therapy. The results showed that both therapy groups experienced reductions in blood pressure and improvements in kidney function. The decrease in systolic/diastolic blood pressure for CCB was 14.7/11.4 mmHg, while for ARB it was 14.2/11.2 mmHg. Increases in GFR, reductions in creatinine, and decreases in urea occurred in both groups with no statistically significant differences (p>0.05). In conclusion, CCB and ARB have comparable clinical effectiveness in controlling blood pressure and improving kidney function parameters in patients with hypertension and end-stage CKD.

Downloads

Download data is not yet available.

References

Alberici, M., & Remuzzi, G. (2021). Hypertension and kidney disease: A deadly connection. Current Hypertension Reports, 23(2), 1–12.

Bakris, G. L., & Sorrentino, M. (2023). Renal considerations in the treatment of hypertension. The American Journal of Medicine, 136(1), 12–19.

Bikbov, B., et al. (2020). Global burden of chronic kidney disease. Nature Reviews Nephrology, 16(10), 585–600.

Buford, G. L. (2019). Age-related changes in cardiovascular function and disease. Circulation, 133(14), 1428–1438.

Burnier, M., & Pruijm, M. (2019). Angiotensin receptor blockers: Mechanisms of action and clinical applications. Journal of Hypertension, 37(1), 3–10.

Departemen Rekam Medis RSI Ibnu Sina Bukittinggi. (2024). Data rekam medis pasien hipertensi dengan gangguan ginjal tahun 2023–2024. Bukittinggi: RSI Ibnu Sina.

Gillis, J. B., & Sullivan, L. M. (2019). Sex and gender differences in hypertension. Hypertension, 67(3), 461–470.

Huang, C. Y., et al. (2020). Calcium channel blockers and renal outcomes in patients with chronic kidney disease: A meta-analysis. Journal of Hypertension, 38(1), 13–21.

KDIGO (Kidney Disease: Improving Global Outcomes). (2020). KDIGO clinical practice guideline for the management of chronic kidney disease. Kidney International Supplements, 10(1), 1–139.

Kurniawan, A. L., Suhardjono, S., & Setiati, S. (2023). The association between uncontrolled hypertension and chronic kidney disease progression in Indonesia. Journal of the Indonesian Medical Association, 73(3), 158–163.

Mann, J. F., et al. (2019). Angiotensin receptor blockers: A review of their pharmacology and clinical applications. Cardiovascular Therapeutics, 37(1), 1–11.

Michel, J. B., et al. (2021). Angiotensin receptor blockers: A comprehensive review of their cardiovascular and renal effects. Journal of Hypertension, 39(12), 2241–2253.

Ramirez, J. A., & Carretero, O. A. (2022). Renoprotective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Journal of the American Society of Nephrology, 33(1), 1–11.

Sarafidis, P. A., & Ruilope, L. M. (2023). The management of hypertension in chronic kidney disease: A comprehensive review. Journal of Hypertension, 41(1), 1–14.

Sica, D. A. (2019). Angiotensin receptor blockers: A review of their pharmacology and clinical applications. Journal of the American College of Cardiology, 73(18), 2197–2210.

Tocci, G., et al. (2020). Calcium channel blockers: Pharmacology, clinical applications, and future perspectives. Current Opinion in Pharmacology, 50, 78–85.

Widiana, N., et al. (2024). Comparative study of ARBs and CCBs in diabetic nephropathy patients in Indonesia. Indonesian Journal of Nephrology and Hypertension, 12(2), 45–54.

Yang, H., et al. (2022). Comparison of calcium channel blockers and angiotensin receptor blockers in patients with chronic kidney disease: A meta-analysis. Clinical and Experimental Nephrology, 26(3), 267–276.